Healthcare Industry News: Artes Medical
News Release - November 28, 2006
Artes Medical Names Diane S. Goostree President and Chief Executive Officer
SAN DIEGO--(HSMN NewsFeed)--Artes Medical, Inc., a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced the appointment of Diane S. Goostree as President and Chief Executive Officer, and to the Board of Directors. Ms. Goostree has served as President and Chief Operating Officer of Artes Medical since March 2006.Ms. Goostree has more than 25 years of industry experience. Prior to joining Artes Medical, Ms. Goostree served as the Senior Vice President, Corporate Development and Operations, for SkinMedica, Inc., a dermatology specialty pharmaceutical company. Ms. Goostree has also held senior positions at Elan Pharmaceuticals, Dura Pharmaceuticals and Sanofi Aventis (previously Marion/Merrell Dow).
Christopher J. Reinhard, Executive Chairman of the Board of Directors of Artes Medical stated, "We are very pleased that Diane, with her leadership and commercialization experience, will be guiding Artes Medical during the next phase of our commercial development as we initiate in the U.S. market our recently FDA approved dermal filler, ArteFill(TM)."
Unlike existing dermal fillers that are completely metabolized by the body, ArteFill represents the first product in a new category of non-resorbable dermal fillers providing a permanent support structure for enduring wrinkle correction. Artes Medical intends to begin marketing and selling ArteFill to dermatologists, plastic surgeons and cosmetic surgeons in the U.S. through the company's direct sales force, beginning in the first quarter of 2007.
"I am excited to take on this expanded role at Artes Medical as we launch our highly differentiated product ArteFill into the aesthetics market in the U.S. I look forward to continuing to work with the outstanding team at Artes to introduce this product for the expanding aesthetic market. We believe that ArteFill addresses the desire of both physicians and patients for a long-lasting dermal filler," said Ms. Goostree.
Ms. Goostree holds a Master of Business Administration degree from the University of Missouri and a Bachelor of Science (Chemical Engineering) from the University of Kansas.
About Artes Medical, Inc.
Artes Medical is a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for the dermatology and plastic surgery markets. The company's initial product, ArteFill, is a non-resorbable aesthetic injectable implant for the correction of facial wrinkles known as nasolabial folds, or smile lines, which will be marketed as a treatment for men and women. Based in San Diego, Calif., Artes Medical was founded in 1999 and is privately-held. Additional information about Artes Medical and ArteFill is available at www.artesmedical.com and www.artefill.com.
Forward-Looking Statements
This news release contains forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
Artes Medical® and ArteFill® are registered trademarks of Artes Medical, Inc.
Source: Artes Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
